Skip to main content

A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

Trial Status: Active

In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in 12-week cycles to patients with unresectable locally advanced pancreatic cancer combined with chemotherapy treatment. Primary Outcome: - Progression-free survival (PFS) in the study population.

Inclusion Criteria

  • Subjects who provide written informed consent to participate in the study
  • Men and women patients 18 years of age and up
  • Have an unresectable, locally advanced pancreatic cancer (AJCC stage III). (Excluded: resectable and borderline resectable patients are ineligible per NCCN criteria)
  • Allocated to receive Gemcitabine + nab-Paclitaxel as first line treatment.
  • Have a target tumor that is accessible for intratumoral administration by EUS (Endoscopic Ultrasound) guidance as determined by the radiologist/gastroenterologist performing the EUS insertion.
  • Have an ECOG performance status of ≤ 1
  • If female and of childbearing potential, have a negative serum or urine pregnancy test during screening. Agree to use a barrier method of contraception if sexually active (both men and women) from the time of administration of the first treatment and for at least 8 weeks after treatment.
  • Have serum creatinine <1.6 mg/dL, INR < 1.5 U, absolute neutrophil count (ANC) > 1.5 x 109/L , platelets ≥ 100 x 109/L , hemoglobin ≥ 9 mg/dL, ALT and AST ≤ 5 x ULN, bilirubin ≤ 1.5 x ULN
  • Have measurable disease. Patients must have clinically and/or radiographically documented measurable primary disease according to RECIST 1.1. At least one site of disease must be unidimensionally measurable. All radiology scans must be performed within 28 days prior to registration

Exclusion Criteria

  • Subjects with resectable and borderline resectable pancreatic cancer
  • Evidence of metastatic disease
  • Other malignancy that would interfere with the current intervention
  • Any evidence of ascites (beyond trace)
  • Bulky celiac adenopathy (≥2.5 cm) or nonadenocarcinoma histology.
  • Any prior therapy for the treatment of pancreatic malignancy (including chemotherapy, immunotherapy, vaccines, monoclonal antibodies, major surgery, or irradiation, whether conventional or investigational).
  • Prior therapy with any hypoxic cytotoxin (hypoxia-targeting drugs).
  • Previously treated malignancies, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancers from which the subject has been disease-free for at least 2 years
  • Severe chronic obstructive or other pulmonary disease with hypoxemia (requires supplementary oxygen, symptoms due to hypoxemia or oxygen saturation <90% by pulse oximetry after a 2 minute walk) or in the opinion of the investigator any physiological state likely to cause systemic or regional hypoxemia
  • History of clinically significant coagulopathy
  • Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery
  • New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within 4months prior to Day 1, unstable arrhythmia or symptomatic peripheral arterial vascular disease
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
  • Subjects who participated in an investigational drug or device study within 28 days prior to study entry
  • Known active infection with HIV, hepatitis B virus, or hepatitis C virus
  • Females who are pregnant or breast-feeding
  • Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
  • Unwillingness or inability to comply with the study protocol for any reason
  • Known allergy to sesame oil

New Jersey

Hackensack University Medical Center
Status: ACTIVE

New York

New York
Icahn School of Medicine at Mount Sinai
Status: ACTIVE
Memorial Sloan Kettering Cancer Center
Status: ACTIVE
Contact: Eileen M. O'Reilly
Phone: 646-888-4182


M D Anderson Cancer Center
Status: ACTIVE

In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in 12-week cycles to patients with unresectable LAPC combined with chemotherapy treatment (Gemcitabine+nab-Paclitaxel). This will be the first study to assess the response rate of the siG12D-LODER in patients with unresectable LAPC. The study is of a two-arm design with one arm receiving siG12D-LODER + chemotherapy, and the other arm receiving only chemotherapy. The investigational agent siG12D-LODER is a miniature biodegradable bio polymeric matrix that encompasses the drug, designed and produced by Silenseed Ltd. The implantation of LODERs is selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures, proved to be highly effective and safe. siG12D-LODER has been studied in the escalating dose Phase I study of 15 patients, and results showed high safety and tolerability profiles, with no single DLT.

Trial Phase Phase II

Trial Type Treatment

Lead Organization
Silenseed Ltd

  • Primary ID SLSG12D-P2
  • Secondary IDs NCI-2018-00398
  • ID NCT01676259